SCHEDULE: Vanguard Reports 0% Stake in Spyre Therapeutics Post-Realignment

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Spyre Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Spyre Therapeutics Inc. Common Stock.
• The filing reports that The Vanguard Group now beneficially owns 0.00 shares, representing 0% of the class of securities.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately, and The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these securities.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a procedural disclosure by The Vanguard Group regarding an internal organizational change, not a reflection of Spyre Therapeutics' operational or financial performance, nor a direct divestment decision.

Risks

• A potential misperception by some investors regarding institutional interest in Spyre Therapeutics Inc. due to The Vanguard Group reporting 0% beneficial ownership, despite the change being due to internal realignment rather than divestment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Spyre Therapeutics Inc.'s future performance or operations.

Management Comments

• Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of Spyre Therapeutics Inc.

Industry Context

StockSavvy.ai notes that internal realignments by large asset managers like The Vanguard Group are operational disclosures common within the financial industry. These changes in reporting structure do not necessarily indicate a shift in investment strategy or sentiment towards the underlying issuer, Spyre Therapeutics Inc., but rather a change in how beneficial ownership is attributed and reported by different entities within the larger Vanguard organization.

Stakeholder Impact

• Shareholders of Spyre Therapeutics Inc. should be aware that The Vanguard Group, as a single reporting entity, no longer reports beneficial ownership, which might alter perceptions of institutional holdings, although affiliated Vanguard entities may still hold shares.

Key Dates

Recommendation

The filing is a procedural disclosure by The Vanguard Group regarding an internal realignment and does not provide new information about Spyre Therapeutics Inc.'s fundamentals, operational performance, or future prospects. Therefore, it does not warrant a change in investment thesis for Spyre Therapeutics Inc.

Keywords

Spyre Therapeutics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Realignment